Details for New Drug Application (NDA): 022220
✉ Email this page to a colleague
NDA 022220 describes TRIVARIS, which is a drug marketed by Allergan and is included in one NDA. Additional details are available on the TRIVARIS profile page.
The generic ingredient in TRIVARIS is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
The generic ingredient in TRIVARIS is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for 022220
| Tradename: | TRIVARIS |
| Applicant: | Allergan |
| Ingredient: | triamcinolone acetonide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 022220
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL | Strength | 8MG/0.1ML (8MG/0.1ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jun 16, 2008 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
